Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II paclitaxel vs irinotecan as second-line therapy in extensive-disease small cell lung cancer
KCT0003330Phase 2Recruiting
- Sponsor
- Chung-Ang University Hospital
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, irinotecan in small cell lung cancer (SCLC), sponsored by Chung-Ang University Hospital. Started Dec 2018; status: recruiting.
02
Drugs
paclitaxelirinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on KCT0003330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003330.